Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of LGX818 Monotherapy Followed by Combination Therapy in BRAF V600 Melanoma
2012-004798-17Phase 2Terminated
- Sponsor
- Novartis
- Start
- Aug 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of encorafenib in melanoma (6 arms), sponsored by Novartis. Primary endpoint: Overall response rate. Started Aug 2013; status: terminated.
02
Drugs
encorafenib
03
Conditions
melanoma
Beyond the preview
Go deeper on 2012-004798-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004798-17.